Atrophy – Global Clinical Trials Review, H2, 2021
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The global atrophy clinical trials review report H2 2021 provides a comprehensive overview of the atrophy clinical trials landscape. This report provides top-line data relating to the clinical trials on atrophy. It includes an overview of the trials count and their average enrolment in top countries conducted globally. The report also includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status, and sponsor type. Moreover, the report provides prominent drug names and trial counts for in-progress trials (based on the number of ongoing trials).
Atrophy clinical trial report consists of 115 trials. Trials conducted by companies in Phase IV, Phase III, Phase II, and Phase I stand at 2, 9, 30, and 9 respectively. Similarly, the trials with different status compile of Completed – 67, Ongoing – 23, Planned – 4, Suspended – 1, Terminated – 10, and withdrawn – 10. Out of 67 completed trials, 30 trials have achieved end point(s).
What are the market dynamics of the global atrophy clinical trials market?
The number of atrophy clinical trials conducted globally has decreased for the period 2016-2020. The average number of patients enrolled was highest in the year 2016. More than 50% of trials have been sponsored by institutions and over 30% by companies. Autologous platelet-rich plasma and undisclosed local anesthetic drugs alone or in combination have the highest number of ongoing atrophy clinical trials.
What are the top regions and countries in the global atrophy clinical trials market?
In total there were 115 clinical trials conducted on atrophy, as of December 2021. Among these trials, 41 clinical trials were conducted in North America.
Asia-Pacific: In the Asia-Pacific region, Japan has the highest number of atrophy clinical trials followed by Australia, India, China, and Hong Kong.
Europe: Among the European countries, France has the highest number of atrophy clinical trials, followed by Germany, Spain, Italy, and the UK.
North America: In the country-wise analysis, the US has the highest number of atrophy clinical trials in North America followed by Canada and Mexico.
Middle East and Africa: Iran has the highest number of atrophy clinical trials followed by Egypt and Israel.
Central and South America: Brazil has the highest number of atrophy clinical trials in the region followed by Antigua and Barbuda, Argentina, and Peru.
G7 countries: Among the G7 (the US, the UK, Germany, France, Italy, Canada, and Japan) countries, France has the highest proportion of atrophy to musculoskeletal disorders clinical trials as of December 2021. In total there were more than 80 clinical trials conducted on atrophy in G7 countries, of which more than 30 clinical trials were in the US.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Brazil has the highest proportion of atrophy to musculoskeletal disorders clinical. In total there were 18 clinical trials conducted on atrophy in E7 Countries, of which five clinical trials were in India.
Global atrophy clinical trials market, by key regions
For more regional insights, download a free report sample
What is the phase-wise outlook of the global atrophy therapeutics clinical trials market?
As of December 2021, there were more than 60 clinical trials in Phase II, of which 11 clinical trials were in progress for the period 1995-2021. During the same period, more than 20 clinical trials are in progress. The trials that were terminated/suspended or withdrawn accounted to more than 20.
Which are the key sponsors in the global atrophy clinical trials sector?
The Lundbeck Foundation, R-Tech Ueno Ltd, Novartis AG, LEO Foundation, Karo Pharma AB, ICON Plc, Dentsply Sirona Inc, Colby Pharmaceutical Co, Advanced Medical Solutions Group Plc, and A+ Science AB are the key sponsors in the atrophy clinical trials market.
Global atrophy clinical trials sector, by key sponsors
To know more about key companies, download a free report sample
Market report scope
Key regions | Asia-Pacific, Europe, North America, Middle East and Africa, and Central and South America |
Key sponsors | The Lundbeck Foundation, R-Tech Ueno Ltd, Novartis AG, LEO Foundation, Karo Pharma AB, ICON Plc, Dentsply Sirona Inc, Colby Pharmaceutical Co, Advanced Medical Solutions Group Plc, and A+ Science AB. |
Scope
- The report provides a snapshot of the global clinical trials landscape.
- Report provides the top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and end point status.
- The report reviews the top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with the reason for unaccomplishment.
- The Report provides enrollment trends for the past five years.
- Report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies with regard to investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top-level analysis of the global clinical trials market which helps in identifying key business opportunities.
- Supports understanding of trials count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country-level.
Colby Pharmaceutical Co
Dentsply Sirona Inc
ICON Plc
Karo Pharma AB
LEO Foundation
Novartis AG
R-Tech Ueno Ltd
The Lundbeck Foundation
A+ Science AB
Table of Contents
Table
Figures
Frequently asked questions
-
Which are the key regions in the global atrophy clinical trials market?
The key regions in the global atrophy therapeutics clinical trials market are Asia-Pacific, Europe, North America, Middle East and Africa, and Central and South America.
-
Which are the key sponsors in the global atrophy clinical trials sector?
The key companies in the global atrophy clinical trials market are The Lundbeck Foundation, R-Tech Ueno Ltd, Novartis AG, LEO Foundation, Karo Pharma AB, ICON Plc, Dentsply Sirona Inc, Colby Pharmaceutical Co, Advanced Medical Solutions Group Plc, and A+ Science AB.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Musculoskeletal Disorders reportsAtrophy – Global Clinical Trials Review, H1, 2021
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData's clinical trial report, “Atrophy – Global Clinical Trials Review, H1, 2021" provides an overview of Atrophy Clinical trials scenario. This report provides top line data relating to the clinical trials on Atrophy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to Buy
– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Colby Pharmaceutical Co
Dentsply Sirona Inc
ICON Plc
Karo Pharma AB
LEO Foundation
Novartis AG
R-Tech Ueno Ltd
The Lundbeck Foundation
A+ Science AB
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.